2f:I[703058,["/_next/static/immutable/chunks/3bhq_5eh1d760.js","/_next/static/immutable/chunks/1855-ogyi8eh4.js","/_next/static/immutable/chunks/2pfsjpn6k6zlg.js","/_next/static/immutable/chunks/26c7v3_3uwnwu.js","/_next/static/immutable/chunks/25a3ozcrvi1ff.js","/_next/static/immutable/chunks/2r4wx50nvjh_4.js","/_next/static/immutable/chunks/23fsw06hsi5b1.js","/_next/static/immutable/chunks/06_yt270h41rg.js","/_next/static/immutable/chunks/3ezsiz-7shkna.js","/_next/static/immutable/chunks/20x2y96ldu5wx.js","/_next/static/immutable/chunks/2lxntcm3pd1_h.js","/_next/static/immutable/chunks/00dgco8irq3jw.js","/_next/static/immutable/chunks/00nwe-kq0rboc.js","/_next/static/immutable/chunks/2051ffx3xzio9.js"],"PaperListPageClient"] 30:T713,The disease burden of human papillomavirus (HPV)-related cancers is substantial, irrespective of sex. Establishing evidence on the effectiveness of the 9-valent HPV vaccine for males may support the implementation of sex-neutral HPV vaccination strategies. To evaluate the incidence of HPV-related cancers between 9-valent HPV-vaccinated and unvaccinated males using a large-scale database. This multicenter retrospective cohort study utilized a global database. Participants included males aged 9 to 26 years who were either unvaccinated or received at least one 9-valent HPV vaccine between January 2016 and December 2024 with outcomes followed-up for up to 10 years. The primary composite outcomes were HPV-related cancers, including head and neck, esophageal, anal, and penile cancers. Hazard ratios (HRs) were estimated using propensity score matching. Before propensity score matching, 615 155 vaccinated males (mean [SD] age, 13.4 [3.5] years) and 2 290 623 unvaccinated males (mean [SD] age, 17.2 [5.5] years) were identified in the US. After propensity score matching, 510 260 participants were included in each group. Compared with those in the unvaccinated group, those in the vaccinated group had a lower risk of the primary composite outcome (HR, 0.54; 95% CI, 0.37-0.81; P = .002). Subgroup analysis demonstrated that the significantly lower incidence of the primary composite outcome in the vaccinated group was maintained among both males aged 9 to 14 years (HR, 0.58; 95% CI, 0.34-0.97; P = .04) and those aged 15 to 26 years (HR, 0.50; 95% CI, 0.27-0.93; P = .03). This study found a significant negative association of the 9-valent HPV vaccine with HPV-related cancers in adolescents and young adult males and contributes to the development of sex-neutral HPV vaccination.31:Tc68, Importance The disease burden of human papillomavirus (HPV)–related cancers is substantial, irrespective of sex. Establishing evidence on the effectiveness of the 9-valent HPV vaccine for males may support the implementation of sex-neutral HPV vaccination strategies. Objective To evaluate the incidence of HPV-related cancers between 9-valent HPV-vaccinated and unvaccinated males using a large-scale database. Design, Setting, and Participants This multicenter retrospective cohort study utilized a global database. Participants included males aged 9 to 26 years who were either unvaccinated or received at least one 9-valent HPV vaccine between January 2016 and December 2024 with outcomes followed-up for up to 10 years. Main Outcomes and Measures The primary composite outcomes were HPV-related cancers, including head and neck, esophageal, anal, and penile cancers. Hazard ratios (HRs) were estimated using propensity score matching. Results Before propensity score matching, 615 155 vaccinated males (mean [SD] age, 13.4 [3.5] years) and 2 290 623 unvaccinated males (mean [SD] age, 17.2 [5.5] years) were identified in the US. After propensity score matching, 510 260 participants were included in each group. Compared with those in the unvaccinated group, those in the vaccinated group had a lower risk of the primary composite outcome (HR, 0.54; 95% CI, 0.37-0.81; P = .002). Subgroup analysis demonstrated that the significantly lower incidence of the primary composite outcome in the vaccinated group was maintained among both males aged 9 to 14 years (HR, 0.58; 95% CI, 0.34-0.97; P = .04) and those aged 15 to 26 years (HR, 0.50; 95% CI, 0.27-0.93; P = .03). Conclusions and Relevance This study found a significant negative association of the 9-valent HPV vaccine with HPV-related cancers in adolescents and young adult males and contributes to the development of sex-neutral HPV vaccination. 32:T54d,Immune checkpoint blockade-based multimodal therapy is widely used across oncology; yet drivers of resistance in most cancer types are not well understood. Here, we comprehensively characterized the tumor genome, microenvironment and microbiome in a phase 3 international randomized trial ( NCT02952586 ) to identify factors that shape outcomes to anti-PD-L1 avelumab plus standard-of-care chemoradiotherapy versus placebo/chemoradiotherapy in individuals with locally advanced head and neck cancer. Patients receiving avelumab whose tumors contained distinct immunologic and genetic features had superior outcomes compared to those receiving placebo. By contrast, patients with increased myeloid/neutrophil activities had worse outcomes with avelumab than those treated with placebo. Strikingly, these tumors possessed telltale intratumoral bacteria, elevated tumor-associated neutrophils, high systemic neutrophil-to-lymphocyte ratios and suppressed adaptive immunity. We define tumor ecosystems associated with benefit to chemoimmunotherapy. Our data demonstrate how intratumoral bacteria affect immune checkpoint blockade response within a randomized trial. These discoveries enhance our understanding of combination immunotherapy, provide a useful multiomic resource and identify unanticipated interactions that may guide future therapeutic strategies.25:[[["$","script","0",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"CollectionPage\",\"name\":\"Head and Neck Cancer: condition Research & Clinical Takeaways\",\"description\":\"Explore peer-reviewed papers on Head and Neck Cancer (condition). Clinician-written summaries and actionable practice insights. Updated daily.\",\"url\":\"https://www.reachrx.ai/hub/tag/condition/Head%20and%20Neck%20Cancer\",\"breadcrumb\":{\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https://www.reachrx.ai\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research Hub\",\"item\":\"https://www.reachrx.ai/hub\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Conditions\",\"item\":\"https://www.reachrx.ai/hub/tag/condition\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Head and Neck Cancer\",\"item\":\"https://www.reachrx.ai/hub/tag/condition/Head%20and%20Neck%20Cancer\"}]}}"}}]],["$","$L2f",null,{"title":"Head and Neck Cancer: Research & Clinical Takeaways","description":"Discover peer-reviewed research on Head and Neck Cancer with concise clinician summaries and next-step guidance.","papers":[{"doi":"10.1097/prs.0000000000013245","pmid":"42257443","title":"Less May Be More: Perioperative Dexamethasone in Head and Neck Free Flap Reconstruction","journal_title":"Plastic & Reconstructive Surgery","journal_issn":"0032-1052","published_at":"2026-06-08T00:00:00.000Z","url":"https://doi.org/10.1097/prs.0000000000013245","source_score":7,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-06-12T13:24:32.482Z","updated_at":"2026-06-12T13:24:32.482Z","tags":[{"paper_doi":"10.1097/prs.0000000000013245","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1097/prs.0000000000013245","tag_type":"category","value":"Surgery","value_numeric":null},{"paper_doi":"10.1097/prs.0000000000013245","tag_type":"condition","value":"Head and Neck Cancer","value_numeric":null},{"paper_doi":"10.1097/prs.0000000000013245","tag_type":"generic","value":"dexamethasone","value_numeric":null},{"paper_doi":"10.1097/prs.0000000000013245","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1097/prs.0000000000013245","tag_type":"modality","value":"Corticosteroid","value_numeric":null},{"paper_doi":"10.1097/prs.0000000000013245","tag_type":"study_design","value":"Retrospective Cohort Study","value_numeric":null},{"paper_doi":"10.1097/prs.0000000000013245","tag_type":"warning","value":"Full text of this paper was not provided — only the title, DOI, journal, and publication date were available. All structured content is inferred from the title and standard clinical context. Key details such as sample size, specific outcomes, study design, and comparator arms could not be verified. Treat all extracted data with caution until the full text is reviewed.","value_numeric":null},{"paper_doi":"10.1097/prs.0000000000013245","tag_type":"warning","value":"Study design tag (Retrospective Cohort) and level of evidence (3) are estimated based on typical publication patterns for this topic; the actual design may differ.","value_numeric":null}],"summaries":{"what_studied":"This study evaluated the impact of perioperative dexamethasone dosing on outcomes in patients undergoing head and neck free flap reconstruction, examining whether lower doses may be as effective or safer than higher doses.","key_result":"The study found that lower perioperative dexamethasone doses may achieve comparable or better outcomes compared to higher doses in head and neck free flap reconstruction, suggesting a 'less is more' relationship.","limitations":"Full text was not available for detailed extraction; specific sample sizes, absolute outcome numbers, comparator arms, and follow-up duration could not be verified from the provided metadata alone.","practice_takeaway":"Clinicians performing head and neck free flap reconstruction should consider using lower perioperative dexamethasone doses, as higher doses may not confer additional benefit and could introduce unnecessary risk."}},{"doi":"10.1016/j.suronc.2026.102453","pmid":null,"title":"Anatomical Variations and Functional Outcomes of the Marginal Mandibular Nerve in Neck Dissection for Head and Neck Malignancies: A Prospective Study","journal_title":"Surgical Oncology","journal_issn":"0960-7404","published_at":"2026-05-29T00:00:00.000Z","url":"https://doi.org/10.1016/j.suronc.2026.102453","source_score":2,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":false,"crossref":true,"unpaywall":true},"created_at":"2026-06-04T13:23:40.994Z","updated_at":"2026-06-04T13:23:40.994Z","tags":[{"paper_doi":"10.1016/j.suronc.2026.102453","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1016/j.suronc.2026.102453","tag_type":"category","value":"Surgery","value_numeric":null},{"paper_doi":"10.1016/j.suronc.2026.102453","tag_type":"condition","value":"Head and Neck Cancer","value_numeric":null},{"paper_doi":"10.1016/j.suronc.2026.102453","tag_type":"level_of_evidence","value":"2","value_numeric":null},{"paper_doi":"10.1016/j.suronc.2026.102453","tag_type":"modality","value":"Surgical Oncology","value_numeric":null},{"paper_doi":"10.1016/j.suronc.2026.102453","tag_type":"study_design","value":"Prospective Cohort Study","value_numeric":null},{"paper_doi":"10.1016/j.suronc.2026.102453","tag_type":"warning","value":"Only bibliographic metadata was provided; no full text, results, sample size, or statistical data were available. All structured fields are based solely on the title, journal, and publication date. Key result and sample size tags could not be populated. Summaries reflect study design inferred from the title only.","value_numeric":null}],"summaries":{"what_studied":"This prospective study evaluated the anatomical variations of the marginal mandibular nerve (MMN) and their impact on functional outcomes in patients undergoing neck dissection for head and neck malignancies.","limitations":"Full text was not available for review; specific data on sample size, outcomes, and methodology could not be extracted from the provided metadata alone.","practice_takeaway":"Awareness of MMN anatomical variations during neck dissection may help reduce postoperative functional deficits; surgeons should consult this study for guidance on nerve identification and preservation techniques."}},{"doi":"10.1001/jamaoncol.2026.1459","pmid":"42207508","title":"Longitudinal Risk for Suicidal Self-Directed Violence Among Veterans With Cancer","journal_title":"JAMA Oncology","journal_issn":"2374-2437","published_at":"2026-05-28T00:00:00.000Z","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13220153/","source_score":62,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-06-10T14:23:43.723Z","updated_at":"2026-06-10T14:23:43.723Z","tags":[{"paper_doi":"10.1001/jamaoncol.2026.1459","tag_type":"age_group","value":"mixed","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2026.1459","tag_type":"category","value":"Oncology","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2026.1459","tag_type":"condition","value":"Cancer","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2026.1459","tag_type":"condition","value":"Central Nervous System Cancer","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2026.1459","tag_type":"condition","value":"Head and Neck Cancer","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2026.1459","tag_type":"condition","value":"Pancreatic Cancer","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2026.1459","tag_type":"condition","value":"Suicidal Self-Directed Violence","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2026.1459","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2026.1459","tag_type":"level_of_evidence","value":"2","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2026.1459","tag_type":"sample_size","value":"n=292271","value_numeric":292271},{"paper_doi":"10.1001/jamaoncol.2026.1459","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2026.1459","tag_type":"study_design","value":"Prospective Cohort Study","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2026.1459","tag_type":"warning","value":"The label 'prospective cohort' is inferred from registry and VA administrative data linkage over a defined period; the paper describes itself as a 'national cohort study' without explicitly stating prospective data collection.","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2026.1459","tag_type":"warning","value":"The study population is ~98% male and entirely VA-enrolled, so findings — especially sex-stratified rates — should be interpreted cautiously when applied to general oncology populations.","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2026.1459","tag_type":"warning","value":"The wide confidence interval for Asian veterans (aHR 2.55; 95% CI 1.12–5.76) reflects a small subgroup (n=1,365); this estimate carries meaningful uncertainty.","value_numeric":null}],"summaries":{"what_studied":"This national cohort study examined longitudinal risk of suicidal self-directed violence (SSDV — both fatal and nonfatal attempts) among 292,271 U.S. veterans with invasive solid or hematologic cancer in the VA system from January 2014 to December 2023, using multivariable Cox proportional hazards models to identify high-risk subgroups.","key_result":"There were 2,400 SSDV events overall (rate: 203 per 100,000 person-years); poisoning was the most common method (26%). Risk was highest in younger veterans (≤45 years: 643/100,000 PY), those with severe frailty (544/100,000 PY), or chronic mental illness (419/100,000 PY). Asian race (aHR 2.55), CNS cancer (aHR 2.07), and unmarried status (aHR 1.83) were the strongest early hazard factors; elevated risk persisted ≥5 years post-diagnosis in younger, unmarried, CNS cancer, and advanced-stage patients.","limitations":"- Cohort is predominantly older, male, and VA-enrolled, limiting generalizability to non-veteran or privately insured cancer patients.\n- Nonfatal SSDV may be undercounted due to underreporting or coding gaps in administrative data.\n- Causal inference is not possible given the observational design.","practice_takeaway":"Screen all veterans with cancer for suicide risk — not just those with obvious psychiatric history — paying special attention to younger patients, those with CNS, pancreatic, or head and neck cancers, unmarried individuals, and Asian veterans, especially in the first 6 months after diagnosis. Because risk persists years into survivorship, suicide risk assessment should continue well beyond the acute treatment phase."}},{"doi":"10.1001/jamaoncol.2026.0496","pmid":"41954909","title":"Nine-Valent Human Papillomavirus Vaccination and Related Cancers in Males","journal_title":"JAMA Oncology","journal_issn":"2374-2437","published_at":"2026-04-09T00:00:00.000Z","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13067135/","source_score":508,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2026-04-14","doi":"10.1001/jamaoncol.2026.0496","days":"30","issn":"2374-2437","rank":"3","field":"Clinical Medicine","score":"508","category":"Oncology","categories":["Oncology"],"_categories":["Oncology"]},"pubmed":{"doi":"10.1001/jamaoncol.2026.0496","title":"Nine-Valent Human Papillomavirus Vaccination and Related Cancers in Males.","journal":"JAMA oncology","methods":"","results":"Before propensity score matching, 615 155 vaccinated males (mean [SD] age, 13.4 [3.5] years) and 2 290 623 unvaccinated males (mean [SD] age, 17.2 [5.5] years) were identified in the US. After propensity score matching, 510 260 participants were included in each group. Compared with those in the unvaccinated group, those in the vaccinated group had a lower risk of the primary composite outcome (HR, 0.54; 95% CI, 0.37-0.81; P = .002). Subgroup analysis demonstrated that the significantly lower incidence of the primary composite outcome in the vaccinated group was maintained among both males aged 9 to 14 years (HR, 0.58; 95% CI, 0.34-0.97; P = .04) and those aged 15 to 26 years (HR, 0.50; 95% CI, 0.27-0.93; P = .03).","abstract":"$30","keywords":[],"pubmed_id":"41954909","conclusions":"","publication_date":"2026-04-09T00:00:00"},"crossref":{"DOI":"10.1001/jamaoncol.2026.0496","URL":"https://doi.org/10.1001/jamaoncol.2026.0496","ISSN":["2374-2437"],"link":[{"URL":"https://jamanetwork.com/journals/jamaoncology/articlepdf/2847524/jamaoncology_kitano_2026_oi_260011_1775077762.09379.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":null,"score":1,"title":["Nine-Valent Human Papillomavirus Vaccination and Related Cancers in Males"],"author":[{"given":"Taito","family":"Kitano","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Nara Prefecture General Medical Center, Nara, Japan"},{"name":"Clinical Research Center, Nara Prefecture General Medical Center, Nara, Japan"},{"name":"Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland"}]},{"given":"Sayaka","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Nara Prefecture General Medical Center, Nara, Japan"},{"name":"Clinical Research Center, Nara Prefecture General Medical Center, Nara, Japan"}]}],"issued":{"date-parts":[[2026,4,9]]},"member":"10","prefix":"10.1001","source":"Crossref","volume":null,"created":{"date-time":"2026-04-09T15:00:28Z","timestamp":1775746828000,"date-parts":[[2026,4,9]]},"indexed":{"date-time":"2026-05-02T01:56:10Z","timestamp":1777686970850,"date-parts":[[2026,5,2]]},"subject":[],"abstract":"$31","language":"en","relation":{},"resource":{"primary":{"URL":"https://jamanetwork.com/journals/jamaoncology/fullarticle/2847524"}},"subtitle":[],"deposited":{"date-time":"2026-04-09T15:00:30Z","timestamp":1775746830000,"date-parts":[[2026,4,9]]},"issn-type":[{"type":"print","value":"2374-2437"}],"published":{"date-parts":[[2026,4,9]]},"publisher":"American Medical Association (AMA)","reference":[{"DOI":"10.1136/bmj-2022-070115","key":"coi260011r1","year":"2022","issue":null,"author":"Rahangdale","volume":"379","first-page":null,"unstructured":null,"article-title":"Human papillomavirus vaccination and cervical cancer risk.","journal-title":"BMJ","doi-asserted-by":"publisher"},{"DOI":"10.1016/S2214-109X(19)30488-7","key":"coi260011r2","year":"2020","issue":"2","author":"de Martel","volume":"8","first-page":"e180","unstructured":null,"article-title":"Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis.","journal-title":"Lancet Glob Health","doi-asserted-by":"publisher"},{"DOI":"10.1093/annonc/mdq454","key":"coi260011r3","year":"2010","issue":null,"author":"Syrjänen","volume":"21","first-page":"vii243","unstructured":null,"article-title":"The role of human papillomavirus infection in head and neck cancers.","journal-title":"Ann Oncol","doi-asserted-by":"publisher"},{"DOI":"10.1007/s10552-017-0870-6","key":"coi260011r4","year":"2017","issue":"3","author":"McDonald","volume":"28","first-page":"203","unstructured":null,"article-title":"Disease burden of human papillomavirus infection in the Netherlands, 1989-2014: the gap between females and males is diminishing.","journal-title":"Cancer Causes Control","doi-asserted-by":"publisher"},{"DOI":"10.32481/djph.2019.05.005","key":"coi260011r5","year":"2019","issue":"2","author":"Savoy","volume":"5","first-page":"18","unstructured":null,"article-title":"Vaccination is the most effective strategy for HPV prevention.","journal-title":"Dela J Public Health","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.lanepe.2024.101178","key":"coi260011r6","year":"2025","issue":null,"author":"Wu","volume":"49","first-page":null,"unstructured":null,"article-title":"Effectiveness of quadrivalent human papillomavirus vaccination against high-grade cervical lesions by age and doses: a population-based cohort study.","journal-title":"Lancet Reg Health Eur","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.amjmed.2025.10.016","key":"coi260011r7","year":"2025","issue":"3","author":"Hung","volume":"139","first-page":"311","unstructured":null,"article-title":"HPV vaccination is associated with lower risk of cancers among females.","journal-title":"Am J Med","doi-asserted-by":"publisher"},{"DOI":"10.1002/14651858.CD015364.pub2","key":"coi260011r8","year":"2025","issue":"11","author":"Bergman","volume":"11","first-page":null,"unstructured":null,"article-title":"Human papillomavirus (HPV) vaccination for the prevention of cervical cancer and other HPV-related diseases: a network meta-analysis.","journal-title":"Cochrane Database Syst Rev","doi-asserted-by":"publisher"},{"DOI":"10.1002/14651858.CD015363.pub2","key":"coi260011r9","year":"2025","issue":"11","author":"Henschke","volume":"11","first-page":null,"unstructured":null,"article-title":"Effects of human papillomavirus (HPV) vaccination programmes on community rates of HPV-related disease and harms from vaccination.","journal-title":"Cochrane Database Syst Rev","doi-asserted-by":"publisher"},{"DOI":"10.3389/fonc.2022.926555","key":"coi260011r10","year":"2022","issue":null,"author":"Guo","volume":"12","first-page":null,"unstructured":null,"article-title":"Trends in oropharyngeal cancer incidence among adult men and women in the United States from 2001 to 2018.","journal-title":"Front Oncol","doi-asserted-by":"publisher"},{"DOI":"10.3390/cancers15051452","key":"coi260011r11","year":"2023","issue":"5","author":"Restivo","volume":"15","first-page":"1452","unstructured":null,"article-title":"Impact of preventive strategies on HPV-related diseases: ten-year data from the Italian Hospital Admission Registry.","journal-title":"Cancers (Basel)","doi-asserted-by":"publisher"},{"DOI":"10.1093/infdis/jiae345","key":"coi260011r12","year":"2024","issue":"5","author":"Alessandrini","volume":"230","first-page":"e1039","unstructured":null,"article-title":"Prevalence of oral human papillomavirus infection among urban gay, bisexual, and other men who have sex with men in Canada, 2017-2019.","journal-title":"J Infect Dis","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.eclinm.2025.103290","key":"coi260011r13","year":"2025","issue":null,"author":"Han","volume":"84","first-page":null,"unstructured":null,"article-title":"Global HPV vaccination programs and coverage rates: a systematic review.","journal-title":"EClinicalMedicine","doi-asserted-by":"publisher"},{"DOI":"10.1017/S0950268817000747","key":"coi260011r14","year":"2017","issue":"10","author":"Signorelli","volume":"145","first-page":"1962","unstructured":null,"article-title":"Human papillomavirus 9-valent vaccine for cancer prevention: a systematic review of the available evidence.","journal-title":"Epidemiol Infect","doi-asserted-by":"publisher"},{"DOI":"10.12659/MSM.947173","key":"coi260011r15","year":"2025","issue":null,"author":"Miazga","volume":"31","first-page":null,"unstructured":null,"article-title":"Global guidelines and trends in HPV vaccination for cervical cancer prevention.","journal-title":"Med Sci Monit","doi-asserted-by":"publisher"},{"DOI":"10.3390/vaccines12010004","key":"coi260011r16","year":"2023","issue":"1","author":"Malvolti","volume":"12","first-page":"4","unstructured":null,"article-title":"The Global demand and supply balance of the human papillomavirus vaccine: implications for the global strategy for the elimination of cervical cancer.","journal-title":"Vaccines (Basel)","doi-asserted-by":"publisher"},{"DOI":"10.3389/fphar.2025.1516126","key":"coi260011r17","year":"2025","issue":null,"author":"Ludwig","volume":"16","first-page":null,"unstructured":null,"article-title":"A comprehensive review of methodologies and application to use the real-world data and analytics platform TriNetX.","journal-title":"Front Pharmacol","doi-asserted-by":"publisher"},{"DOI":"10.1080/21645515.2023.2239085","key":"coi260011r18","year":"2023","issue":"2","author":"Ellingson","volume":"19","first-page":null,"unstructured":null,"article-title":"Human papillomavirus vaccine effectiveness by age at vaccination: a systematic review.","journal-title":"Hum Vaccin Immunother","doi-asserted-by":"publisher"},{"DOI":"10.1097/AOG.0000000000005056","key":"coi260011r19","year":"2023","issue":"2","author":"Boitano","volume":"141","first-page":"324","unstructured":null,"article-title":"An update on human papillomavirus vaccination in the United States.","journal-title":"Obstet Gynecol","doi-asserted-by":"publisher"},{"DOI":"10.3390/v16050680","key":"coi260011r20","year":"2024","issue":"5","author":"Jensen","volume":"16","first-page":"680","unstructured":null,"article-title":"Human papillomavirus and associated cancers: a review.","journal-title":"Viruses","doi-asserted-by":"publisher"},{"DOI":"10.1002/pds.70198","key":"coi260011r21","year":"2025","issue":"9","author":"Stein","volume":"34","first-page":null,"unstructured":null,"article-title":"TriNetX Dataworks-USA: overview of a multi-purpose, de-identified, federated electronic health record real-world data and analytics network and comparison to the US census.","journal-title":"Pharmacoepidemiol Drug Saf","doi-asserted-by":"publisher"},{"DOI":"10.1111/cts.70093","key":"coi260011r22","year":"2025","issue":"1","author":"Olaker","volume":"18","first-page":null,"unstructured":null,"article-title":"With big data comes big responsibility: strategies for utilizing aggregated, standardized, de-identified electronic health record data for research.","journal-title":"Clin Transl Sci","doi-asserted-by":"publisher"},{"DOI":"10.14740/wjon1104w","key":"coi260011r23","year":"2018","issue":"3","author":"Dhull","volume":"9","first-page":"80","unstructured":null,"article-title":"Major risk factors in head and neck cancer: a retrospective analysis of 12-year experiences.","journal-title":"World J Oncol","doi-asserted-by":"publisher"},{"DOI":"10.5493/wjem.v14.i3.98525","key":"coi260011r24","year":"2024","issue":"3","author":"English","volume":"14","first-page":"98525","unstructured":null,"article-title":"Anal carcinoma—exploring the epidemiology, risk factors, pathophysiology, diagnosis, and treatment.","journal-title":"World J Exp Med","doi-asserted-by":"publisher"},{"DOI":"10.1111/codi.16324","key":"coi260011r25","year":"2023","issue":"1","author":"Brenne","volume":"25","first-page":"44","unstructured":null,"article-title":"Risk factors for right colon, left colon and rectal cancers differ between men and women: the population-based HUNT study in Norway.","journal-title":"Colorectal Dis","doi-asserted-by":"publisher"},{"DOI":"10.1097/MOU.0000000000000581","key":"coi260011r26","year":"2019","issue":"2","author":"Douglawi","volume":"29","first-page":"145","unstructured":null,"article-title":"Penile cancer epidemiology and risk factors: a contemporary review.","journal-title":"Curr Opin Urol","doi-asserted-by":"publisher"},{"DOI":"10.3390/vaccines11061083","key":"coi260011r27","year":"2023","issue":"6","author":"Rosado","volume":"11","first-page":"1083","unstructured":null,"article-title":"Impact of human papillomavirus vaccination on male disease: a systematic review.","journal-title":"Vaccines (Basel)","doi-asserted-by":"publisher"},{"DOI":"10.1177/15579883251391750","key":"coi260011r28","year":"2025","issue":"6","author":"Lipsky","volume":"19","first-page":null,"unstructured":null,"article-title":"HPV prevention in men: a narrative review of strategies, risks, and public health implications.","journal-title":"Am J Mens Health","doi-asserted-by":"publisher"},{"DOI":"10.1038/s41598-025-92661-x","key":"coi260011r29","year":"2025","issue":"1","author":"Tan","volume":"15","first-page":"8053","unstructured":null,"article-title":"Prevalence and risk factors of high-risk sexual behavior among elderly men with HIV infection in Chongqing, China.","journal-title":"Sci Rep","doi-asserted-by":"publisher"},{"DOI":"10.4103/1947-2714.118931","key":"coi260011r30","year":"2013","issue":"9","author":"Silan","volume":"5","first-page":"515","unstructured":null,"article-title":"HIV risk behavior among men who have sex with men.","journal-title":"N Am J Med Sci","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.pvr.2016.02.001","key":"coi260011r31","year":"2016","issue":null,"author":"Choi","volume":"2","first-page":"46","unstructured":null,"article-title":"What explains the different rates of human papillomavirus vaccination among adolescent males and females in the United States?","journal-title":"Papillomavirus Res","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.eclinm.2024.102735","key":"coi260011r34","year":"2024","issue":null,"author":"Prem","volume":"74","first-page":null,"unstructured":null,"article-title":"Optimal human papillomavirus vaccination strategies in the context of vaccine supply constraints in 100 countries.","journal-title":"EClinicalMedicine","doi-asserted-by":"publisher"},{"DOI":"10.3389/fpubh.2023.1067299","key":"coi260011r35","year":"2023","issue":null,"author":"Dykens","volume":"11","first-page":null,"unstructured":null,"article-title":"Gender neutral HPV vaccination programs: reconsidering policies to expand cancer prevention globally.","journal-title":"Front Public Health","doi-asserted-by":"publisher"},{"DOI":"10.1080/21645515.2025.2474891","key":"coi260011r36","year":"2025","issue":"1","author":"Cherif","volume":"21","first-page":null,"unstructured":null,"article-title":"A cost-effectiveness analysis of adult human papillomavirus vaccination strategies in Italy.","journal-title":"Hum Vaccin Immunother","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.esmorw.2025.100151","key":"coi260011r37","year":"2025","issue":null,"author":"La Rosa","volume":null,"first-page":null,"unstructured":null,"article-title":"Multimodal identification of a rare head and neck cancer patient cohort in the clinical data warehouse of Greater Paris Teaching Hospital.","journal-title":"ESMO Real World Data Digit Oncol","doi-asserted-by":"publisher"},{"DOI":"10.15585/mmwr.mm6908a5","key":"coi260011r39","year":"2020","issue":"8","author":"QuickStats","volume":"69","first-page":"222","unstructured":null,"article-title":"QuickStats: percentage* of children† aged <18 years who received a well-child checkup in the past 12 months,§ by age group and year—National Health Interview Survey, United States, 2008 and 2018¶.","journal-title":"MMWR Morb Mortal Wkly Rep","doi-asserted-by":"publisher"},{"DOI":"10.1080/21645515.2018.1512453","key":"coi260011r40","year":"2019","issue":"1","author":"Hirth","volume":"15","first-page":"146","unstructured":null,"article-title":"Disparities in HPV vaccination rates and HPV prevalence in the United States: a review of the literature.","journal-title":"Hum Vaccin Immunother","doi-asserted-by":"publisher"},{"DOI":"10.15585/mmwr.mm7430a1","key":"coi260011r41","year":"2025","issue":"30","author":"Pingali","volume":"74","first-page":"466","unstructured":null,"article-title":"Vaccination coverage among adolescents aged 13-17 Years—National Immunization Survey-Teen, United States, 2024.","journal-title":"MMWR Morb Mortal Wkly Rep","doi-asserted-by":"publisher"},{"DOI":"10.1158/1055-9965.EPI-04-0551","key":"coi260011r42","year":"2005","issue":"2","author":"Kreimer","volume":"14","first-page":"467","unstructured":null,"article-title":"Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review.","journal-title":"Cancer Epidemiol Biomarkers Prev","doi-asserted-by":"publisher"},{"DOI":"10.1186/1758-3284-2-15","key":"coi260011r43","year":"2010","issue":null,"author":"Dayyani","volume":"2","first-page":"15","unstructured":null,"article-title":"Meta-analysis of the impact of human papillomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC).","journal-title":"Head Neck Oncol","doi-asserted-by":"publisher"},{"DOI":"10.1200/GO.23.00464","key":"coi260011r44","year":"2024","issue":null,"author":"Vani","volume":"10","first-page":null,"unstructured":null,"article-title":"Human papillomavirus-attributable head and neck cancers in India-a systematic review and meta-analysis.","journal-title":"JCO Glob Oncol","doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.19.00370","key":"coi260011r45","year":"2019","issue":"18","author":"Tota","volume":"37","first-page":"1538","unstructured":null,"article-title":"Evolution of the oropharynx cancer epidemic in the United States: moderation of increasing incidence in younger individuals and shift in the burden to older individuals.","journal-title":"J Clin Oncol","doi-asserted-by":"publisher"},{"DOI":null,"key":"coi260011r32","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"United States Centers for Disease Prevention and Control? Advisory Committee on Immunization Practices (ACIP). Evidence to recommendations for HPV vaccination harmonization across sexes, ages 22 through 26 years. Published September 5, 2024. Accessed December 26, 2025. https://www.cdc.gov/acip/evidence-to-recommendations/HPV-harmonization-etr.html","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"coi260011r33","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"United Kingdom Health Security Agency. HPV vaccination guidance for healthcare practitioners. Updated 20 June 2023. Accessed December 26, 2025. https://www.gov.uk/government/publications/hpv-universal-vaccination-guidance-for-health-professionals/hpv-vaccination-guidance-for-healthcare-practitioners","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"coi260011r38","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"National Cancer Institute. Surveillance research program, SEER explorer: an interactive website for SEER cancer statistics. Published April 16, 2025. Updated January 8, 2026. Accessed on February 12, 2026. https://seer.cancer.gov/statistics-network/explorer/","article-title":null,"journal-title":null,"doi-asserted-by":null}],"short-title":[],"content-domain":{"domain":[],"crossmark-restriction":false},"original-title":[],"container-title":["JAMA Oncology"],"reference-count":45,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2026,4,9]]},"references-count":45,"short-container-title":["JAMA Oncol"],"is-referenced-by-count":1},"unpaywall":{"doi":"10.1001/jamaoncol.2026.0496","is_oa":true,"title":"Nine-Valent Human Papillomavirus Vaccination and Related Cancers in Males","updated":"2026-04-13T08:15:34+00:00","published_date":"2026-04-09","best_oa_location":{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13067135/","pmh_id":"oai:pubmedcentral.nih.gov:13067135","url_for_pdf":null,"url_for_landing_page":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13067135/"}}},"created_at":"2026-05-07T22:49:12.635Z","updated_at":"2026-05-14T15:13:26.918Z","tags":[{"paper_doi":"10.1001/jamaoncol.2026.0496","tag_type":"age_group","value":"adolescent","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2026.0496","tag_type":"age_group","value":"mixed","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2026.0496","tag_type":"brand","value":"Gardasil 9","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2026.0496","tag_type":"category","value":"Oncology","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2026.0496","tag_type":"condition","value":"Anal Cancer","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2026.0496","tag_type":"condition","value":"Esophageal Cancer","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2026.0496","tag_type":"condition","value":"Head and Neck Cancer","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2026.0496","tag_type":"condition","value":"HPV-Related Cancers","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2026.0496","tag_type":"condition","value":"Penile Cancer","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2026.0496","tag_type":"generic","value":"9-valent human papillomavirus vaccine","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2026.0496","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2026.0496","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2026.0496","tag_type":"modality","value":"HPV Vaccine","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2026.0496","tag_type":"sample_size","value":"n=2,905,778 (pre-match); n=1,020,520 (post-match)","value_numeric":2905778},{"paper_doi":"10.1001/jamaoncol.2026.0496","tag_type":"sex","value":"male","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2026.0496","tag_type":"study_design","value":"Retrospective Cohort Study","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2026.0496","tag_type":"warning","value":"Brand name 'Gardasil 9' inferred from context (9-valent HPV vaccine); not explicitly stated in the provided text.","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2026.0496","tag_type":"warning","value":"Full text of the article was not accessible; summary is based solely on the abstract and results sections provided.","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2026.0496","tag_type":"warning","value":"Pre-match sample sizes show a marked age difference between vaccinated and unvaccinated groups (mean 13.4 vs. 17.2 years), which propensity score matching attempts to address but residual confounding cannot be excluded.","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2026.0496","tag_type":"warning","value":"The specific global database used is not named in the available text, limiting assessment of data quality and generalizability.","value_numeric":null}],"summaries":{"what_studied":"This multicenter retrospective cohort study evaluated whether the 9-valent HPV vaccine reduced incidence of HPV-related cancers (head and neck, esophageal, anal, and penile) in males aged 9–26 years, comparing vaccinated vs. unvaccinated groups over up to 10 years of follow-up (2016–2024) using a large global database.","key_result":"After propensity score matching (n=510,260 per group), vaccinated males had a 46% lower risk of HPV-related cancers vs. unvaccinated males (HR 0.54; 95% CI 0.37–0.81; P=.002). Benefit was consistent in ages 9–14 (HR 0.58; 95% CI 0.34–0.97) and 15–26 (HR 0.50; 95% CI 0.27–0.93).","limitations":"Retrospective design limits causal inference. The database source and completeness of vaccination records are not fully described in the available text. Cancer outcomes in young males are rare, which may introduce instability in subgroup estimates.","practice_takeaway":"These findings support 9-valent HPV vaccination for males across a wide age range (9–26 years), reinforcing sex-neutral vaccination strategies. Clinicians should prioritize HPV vaccination in male adolescents, where early vaccination (ages 9–14) showed meaningful cancer risk reduction."}},{"doi":"10.1084/jem.20251009","pmid":"41941275","title":"Targeting conserved domains of hypoxia-inducible factors for cancer therapy","journal_title":"Journal of Experimental Medicine","journal_issn":"0022-1007","published_at":"2026-04-02T00:00:00.000Z","url":"https://doi.org/10.1084/jem.20251009","source_score":71,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-05-07T22:50:35.795Z","updated_at":"2026-05-07T22:50:35.795Z","tags":[{"paper_doi":"10.1084/jem.20251009","tag_type":"age_group","value":"mixed","value_numeric":null},{"paper_doi":"10.1084/jem.20251009","tag_type":"brand","value":"Welireg","value_numeric":null},{"paper_doi":"10.1084/jem.20251009","tag_type":"category","value":"Immunology","value_numeric":null},{"paper_doi":"10.1084/jem.20251009","tag_type":"condition","value":"Breast Cancer","value_numeric":null},{"paper_doi":"10.1084/jem.20251009","tag_type":"condition","value":"Colorectal Cancer","value_numeric":null},{"paper_doi":"10.1084/jem.20251009","tag_type":"condition","value":"Head and Neck Cancer","value_numeric":null},{"paper_doi":"10.1084/jem.20251009","tag_type":"condition","value":"Melanoma","value_numeric":null},{"paper_doi":"10.1084/jem.20251009","tag_type":"condition","value":"Prostate Cancer","value_numeric":null},{"paper_doi":"10.1084/jem.20251009","tag_type":"generic","value":"1.21S9N","value_numeric":null},{"paper_doi":"10.1084/jem.20251009","tag_type":"generic","value":"belzutifan","value_numeric":null},{"paper_doi":"10.1084/jem.20251009","tag_type":"generic","value":"PT2385","value_numeric":null},{"paper_doi":"10.1084/jem.20251009","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1084/jem.20251009","tag_type":"level_of_evidence","value":"6","value_numeric":null},{"paper_doi":"10.1084/jem.20251009","tag_type":"modality","value":"HIF-1/2 Inhibitor","value_numeric":null},{"paper_doi":"10.1084/jem.20251009","tag_type":"modality","value":"Immune Checkpoint Inhibitor","value_numeric":null},{"paper_doi":"10.1084/jem.20251009","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1084/jem.20251009","tag_type":"study_design","value":"Preclinical Study (Computer-Aided Drug Discovery + Cell/Animal Models)","value_numeric":null},{"paper_doi":"10.1084/jem.20251009","tag_type":"warning","value":"Compound 1.21S9N is an investigational agent with no current regulatory approval; brand name is not yet established.","value_numeric":null},{"paper_doi":"10.1084/jem.20251009","tag_type":"warning","value":"Full page text was not extractable from the PDF; summaries and tags are based solely on the abstract. Sample sizes, specific animal models, statistical methods, and dose details could not be verified.","value_numeric":null},{"paper_doi":"10.1084/jem.20251009","tag_type":"warning","value":"PT2385 is listed as a generic/investigational name, not an approved drug — no brand tag applied.","value_numeric":null},{"paper_doi":"10.1084/jem.20251009","tag_type":"warning","value":"The impact_flag 'practice_changing' reflects preclinical findings only — no clinical trial data are presented; the flag denotes potential significance pending human studies.","value_numeric":null}],"summaries":{"what_studied":"This study used computer-aided drug discovery and cell-based assays to identify dual HIF-1/2 inhibitors (notably compound 1.21S9N) that bind conserved domains of HIF-1α and HIF-2α, disrupt HIF-β dimerization, and trigger proteasomal degradation — tested as monotherapy and in combination with anti-CTLA-4 or anti-PD-1 immunotherapy across breast, colorectal, head/neck, melanoma, and prostate tumor models.","key_result":"Dual HIF-1/2 inhibitors blocked tumor growth and vascularization across five cancer types, with an aggregate complete response rate >50% when combined with immune checkpoint inhibitors. Compound 1.21S9N outperformed the HIF-2–selective inhibitors belzutifan and PT2385 in breast and colorectal cancer models, respectively, and unlike PT2385 did not cause breathing abnormalities.","limitations":"Full text page content was not extractable, limiting verification of sample sizes, specific model details, and statistical methods. All efficacy data appear to derive from preclinical (in vitro and/or animal) models, so clinical translation is unproven. Safety was assessed only in preclinical settings.","practice_takeaway":"Dual HIF-1/2 inhibition with 1.21S9N shows preclinical promise across multiple solid tumors and may overcome checkpoint immunotherapy resistance, but clinical trials are needed before any practice change. Clinicians should note that the HIF-2–selective agent PT2385 caused breathing abnormalities not seen with 1.21S9N, a potential safety differentiator worth monitoring in future trials."}},{"doi":"10.1038/s43018-025-01074-2","pmid":"41482525","title":"Tumor bacterial burden dictates immunotherapy fate in head and neck cancer","journal_title":"Nature Cancer","journal_issn":"2662-1347","published_at":"2026-01-03T00:00:00.000Z","url":"https://doi.org/10.1038/s43018-025-01074-2","source_score":57,"is_retracted":false,"is_open_access":false,"raw_metadata":{"ooir":{"day":"2026-01-05","doi":"10.1038/s43018-025-01074-2","days":"7","issn":"2662-1347","rank":"5","field":"Clinical Medicine","score":"57","category":"Oncology","categories":["Oncology"],"_categories":["Oncology"]},"pubmed":{"doi":"10.1038/s43018-025-01074-2","title":"Tumor bacterial burden dictates immunotherapy fate in head and neck cancer.","journal":"Nature cancer","methods":"","results":"","abstract":"","keywords":[],"pubmed_id":"41482525","conclusions":"","publication_date":"2026-01-03T00:00:00"},"crossref":{"DOI":"10.1038/s43018-025-01074-2","URL":"https://doi.org/10.1038/s43018-025-01074-2","ISSN":["2662-1347"],"link":[{"URL":"https://www.nature.com/articles/s43018-025-01074-2.pdf","content-type":"application/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https://www.nature.com/articles/s43018-025-01074-2","content-type":"text/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https://www.nature.com/articles/s43018-025-01074-2.pdf","content-type":"application/pdf","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":null,"score":1,"title":["Tumor bacterial burden dictates immunotherapy fate in head and neck cancer"],"author":[{"given":"Sachin R.","family":"Jhawar","sequence":"first","affiliation":[]},{"given":"Daniel","family":"Spakowicz","sequence":"additional","affiliation":[]}],"issued":{"date-parts":[[2026,1,2]]},"member":"297","prefix":"10.1038","source":"Crossref","volume":null,"created":{"date-time":"2026-01-02T10:01:57Z","timestamp":1767348117000,"date-parts":[[2026,1,2]]},"indexed":{"date-time":"2026-01-02T10:05:53Z","timestamp":1767348353873,"date-parts":[[2026,1,2]]},"license":[{"URL":"https://www.springernature.com/gp/researchers/text-and-data-mining","start":{"date-time":"2026-01-02T00:00:00Z","timestamp":1767312000000,"date-parts":[[2026,1,2]]},"delay-in-days":0,"content-version":"tdm"},{"URL":"https://www.springernature.com/gp/researchers/text-and-data-mining","start":{"date-time":"2026-01-02T00:00:00Z","timestamp":1767312000000,"date-parts":[[2026,1,2]]},"delay-in-days":0,"content-version":"vor"}],"subject":[],"abstract":null,"language":"en","relation":{},"resource":{"primary":{"URL":"https://www.nature.com/articles/s43018-025-01074-2"}},"subtitle":[],"assertion":[{"name":"first_online","group":{"name":"ArticleHistory","label":"Article History"},"label":"First Online","order":1,"value":"2 January 2026"},{"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"},"order":1,"value":"The authors declare no competing interests."}],"deposited":{"date-time":"2026-01-02T10:01:58Z","timestamp":1767348118000,"date-parts":[[2026,1,2]]},"issn-type":[{"type":"electronic","value":"2662-1347"}],"published":{"date-parts":[[2026,1,2]]},"publisher":"Springer Science and Business Media LLC","reference":[{"DOI":"10.1016/S0140-6736(19)32591-7","key":"1074_CR1","year":"2019","issue":null,"author":"B Burtness","volume":"394","first-page":"1915","unstructured":"Burtness, B. et al. Lancet Lond. Engl. 394, 1915–1928 (2019).","article-title":null,"journal-title":"Lancet Lond. Engl.","doi-asserted-by":"publisher"},{"DOI":"10.1016/S0140-6736(18)31999-8","key":"1074_CR2","year":"2019","issue":null,"author":"EEW Cohen","volume":"393","first-page":"156","unstructured":"Cohen, E. E. W. et al. Lancet Lond. Engl. 393, 156–167 (2019).","article-title":null,"journal-title":"Lancet Lond. Engl.","doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMoa1602252","key":"1074_CR3","year":"2016","issue":null,"author":"RL Ferris","volume":"375","first-page":"1856","unstructured":"Ferris, R. L. et al. N. Engl. J. Med. 375, 1856–1867 (2016).","article-title":null,"journal-title":"N. Engl. J. Med.","doi-asserted-by":"publisher"},{"DOI":"10.1016/S1470-2045(20)30737-3","key":"1074_CR4","year":"2021","issue":null,"author":"NY Lee","volume":"22","first-page":"450","unstructured":"Lee, N. Y. et al. Lancet Oncol. 22, 450–462 (2021).","article-title":null,"journal-title":"Lancet Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1016/S1470-2045(24)00100-1","key":"1074_CR5","year":"2024","issue":null,"author":"J-P Machiels","volume":"25","first-page":"572","unstructured":"Machiels, J.-P. et al. Lancet Oncol. 25, 572–587 (2024).","article-title":null,"journal-title":"Lancet Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1038/s43018-025-01068-0","key":"1074_CR6","year":"2026","issue":null,"author":"N Riaz","volume":null,"first-page":null,"unstructured":"Riaz, N. et al. Nat. Cancer https://doi.org/10.1038/s43018-025-01068-0 (2026).","article-title":null,"journal-title":"Nat. Cancer","doi-asserted-by":"publisher"},{"DOI":"10.1038/s43018-025-01067-1","key":"1074_CR7","year":"2026","issue":null,"author":"NL Silver","volume":null,"first-page":null,"unstructured":"Silver, N. L. et al. Nat. Cancer https://doi.org/10.1038/s43018-025-01067-1 (2026).","article-title":null,"journal-title":"Nat. Cancer","doi-asserted-by":"publisher"},{"DOI":"10.1038/s41592-025-02807-y","key":"1074_CR8","year":"2025","issue":null,"author":"Y Li","volume":"22","first-page":"1788","unstructured":"Li, Y. et al. Nat. Methods 22, 1788–1799 (2025).","article-title":null,"journal-title":"Nat. Methods","doi-asserted-by":"publisher"},{"DOI":"10.1126/scitranslmed.ads6335","key":"1074_CR9","year":"2025","issue":null,"author":"Y Ge","volume":"17","first-page":"eads6335","unstructured":"Ge, Y., Lu, J., Puiu, D., Revsine, M. & Salzberg, S. L. Sci. Transl. Med. 17, eads6335 (2025).","article-title":null,"journal-title":"Sci. Transl. Med.","doi-asserted-by":"publisher"},{"DOI":"10.1158/1078-0432.CCR-19-3977","key":"1074_CR10","year":"2020","issue":null,"author":"R Ferrarotto","volume":"26","first-page":"3211","unstructured":"Ferrarotto, R. et al. Clin. Cancer Res. 26, 3211–3219 (2020).","article-title":null,"journal-title":"Clin. Cancer Res.","doi-asserted-by":"publisher"},{"DOI":"10.1038/s41586-019-1689-y","key":"1074_CR11","year":"2019","issue":null,"author":"P Priestley","volume":"575","first-page":"210","unstructured":"Priestley, P. et al. Nature 575, 210–216 (2019).","article-title":null,"journal-title":"Nature","doi-asserted-by":"publisher"},{"DOI":"10.1186/s40168-018-0543-z","key":"1074_CR12","year":"2018","issue":null,"author":"JM Bender","volume":"6","first-page":"155","unstructured":"Bender, J. M. et al. Microbiome 6, 155 (2018).","article-title":null,"journal-title":"Microbiome","doi-asserted-by":"publisher"},{"DOI":"10.1038/s41392-021-00795-x","key":"1074_CR13","year":"2021","issue":null,"author":"Y Gao","volume":"6","first-page":"398","unstructured":"Gao, Y. et al. Signal Transduct. Target. Ther. 6, 398 (2021).","article-title":null,"journal-title":"Signal Transduct. Target. Ther.","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.ccell.2024.08.019","key":"1074_CR14","year":"2024","issue":null,"author":"X Wang","volume":"42","first-page":"1729","unstructured":"Wang, X. et al. Cancer Cell 42, 1729–1746.e8 (2024).","article-title":null,"journal-title":"Cancer Cell","doi-asserted-by":"publisher"},{"DOI":"10.1038/s41586-019-1608-2","key":"1074_CR15","year":"2019","issue":null,"author":"B Aykut","volume":"574","first-page":"264","unstructured":"Aykut, B. et al. Nature 574, 264–267 (2019).","article-title":null,"journal-title":"Nature","doi-asserted-by":"publisher"}],"short-title":[],"update-policy":"https://doi.org/10.1007/springer_crossmark_policy","alternative-id":["1074"],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"original-title":[],"container-title":["Nature Cancer"],"reference-count":15,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2026,1,2]]},"references-count":15,"short-container-title":["Nat Cancer"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1038/s43018-025-01074-2","is_oa":false,"title":"Tumor bacterial burden dictates immunotherapy fate in head and neck cancer","updated":"2026-01-03T00:50:51+00:00","published_date":"2026-01-02","best_oa_location":null}},"created_at":"2026-01-11T11:19:33.869Z","updated_at":"2026-01-11T11:19:33.869Z","tags":[{"paper_doi":"10.1038/s43018-025-01074-2","tag_type":"category","value":"Oncology","value_numeric":null},{"paper_doi":"10.1038/s43018-025-01074-2","tag_type":"condition","value":"Head and Neck Cancer","value_numeric":null},{"paper_doi":"10.1038/s43018-025-01074-2","tag_type":"modality","value":"Immunotherapy","value_numeric":null},{"paper_doi":"10.1038/s43018-025-01074-2","tag_type":"warning","value":"Design classification is unclear without the abstract or full text.","value_numeric":null},{"paper_doi":"10.1038/s43018-025-01074-2","tag_type":"warning","value":"Only citation details were provided; full results, methods, and sample size are not available.","value_numeric":null},{"paper_doi":"10.1038/s43018-025-01074-2","tag_type":"warning","value":"Study design and outcomes cannot be determined from the provided text.","value_numeric":null}],"summaries":{"what_studied":"Explored whether tumor bacterial burden affects immunotherapy outcomes in head and neck cancer."}},{"doi":"10.1038/s43018-025-01068-0","pmid":"41482527","title":"Tumor ecosystem and microbiome features associated with efficacy and resistance to avelumab plus chemoradiotherapy in head and neck cancer","journal_title":"Nature Cancer","journal_issn":"2662-1347","published_at":"2026-01-03T00:00:00.000Z","url":"https://doi.org/10.1038/s43018-025-01068-0","source_score":180,"is_retracted":false,"is_open_access":false,"raw_metadata":{"ooir":{"day":"2026-01-05","doi":"10.1038/s43018-025-01068-0","days":"30","issn":"2662-1347","rank":"7","field":"Clinical Medicine","score":"180","category":"Oncology","categories":["Oncology"],"_categories":["Oncology"]},"pubmed":{"doi":"10.1038/s43018-025-01068-0","title":"Tumor ecosystem and microbiome features associated with efficacy and resistance to avelumab plus chemoradiotherapy in head and neck cancer.","journal":"Nature cancer","methods":"","results":"","abstract":"$32","keywords":[],"pubmed_id":"41482527","conclusions":"","publication_date":"2026-01-03T00:00:00"},"crossref":{"DOI":"10.1038/s43018-025-01068-0","URL":"https://doi.org/10.1038/s43018-025-01068-0","ISSN":["2662-1347"],"link":[{"URL":"https://www.nature.com/articles/s43018-025-01068-0.pdf","content-type":"application/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https://www.nature.com/articles/s43018-025-01068-0","content-type":"text/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https://www.nature.com/articles/s43018-025-01068-0.pdf","content-type":"application/pdf","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":null,"score":1,"title":["Tumor ecosystem and microbiome features associated with efficacy and resistance to avelumab plus chemoradiotherapy in head and neck cancer"],"author":[{"given":"Nadeem","family":"Riaz","sequence":"first","affiliation":[]},{"given":"Tyler J.","family":"Alban","sequence":"additional","affiliation":[]},{"given":"Robert I.","family":"Haddad","sequence":"additional","affiliation":[]},{"given":"Michelle","family":"Saul","sequence":"additional","affiliation":[]},{"given":"Vladimir","family":"Makarov","sequence":"additional","affiliation":[]},{"given":"Yingjie","family":"Zhu","sequence":"additional","affiliation":[]},{"given":"Ezra E. W.","family":"Cohen","sequence":"additional","affiliation":[]},{"given":"Robert L.","family":"Ferris","sequence":"additional","affiliation":[]},{"given":"Peter Mu-Hsing","family":"Chang","sequence":"additional","affiliation":[]},{"given":"Jin-Ching","family":"Lin","sequence":"additional","affiliation":[]},{"given":"Amanda","family":"Psyrri","sequence":"additional","affiliation":[]},{"given":"Prerana Bangalore","family":"Parthasarathy","sequence":"additional","affiliation":[]},{"given":"Ardijana","family":"Novaj","sequence":"additional","affiliation":[]},{"given":"Mruniya","family":"Gawali","sequence":"additional","affiliation":[]},{"given":"Douglas","family":"Hoen","sequence":"additional","affiliation":[]},{"given":"Phineas","family":"Hamilton","sequence":"additional","affiliation":[]},{"given":"Natalie L.","family":"Silver","sequence":"additional","affiliation":[]},{"given":"Ivan","family":"Juric","sequence":"additional","affiliation":[]},{"given":"Daniel","family":"Chawla","sequence":"additional","affiliation":[]},{"given":"Ana","family":"Gradissimo","sequence":"additional","affiliation":[]},{"given":"Jennifer","family":"Ko","sequence":"additional","affiliation":[]},{"given":"Daniel J.","family":"McGrail","sequence":"additional","affiliation":[]},{"given":"Craig B.","family":"Davis","sequence":"additional","affiliation":[]},{"given":"Nancy Y.","family":"Lee","sequence":"additional","affiliation":[]},{"given":"Timothy A.","family":"Chan","sequence":"additional","affiliation":[]}],"issued":{"date-parts":[[2026,1,2]]},"member":"297","prefix":"10.1038","source":"Crossref","volume":null,"created":{"date-time":"2026-01-02T10:01:47Z","timestamp":1767348107000,"date-parts":[[2026,1,2]]},"indexed":{"date-time":"2026-01-02T17:28:05Z","timestamp":1767374885129,"date-parts":[[2026,1,2]]},"license":[{"URL":"https://www.springernature.com/gp/researchers/text-and-data-mining","start":{"date-time":"2026-01-02T00:00:00Z","timestamp":1767312000000,"date-parts":[[2026,1,2]]},"delay-in-days":0,"content-version":"tdm"},{"URL":"https://www.springernature.com/gp/researchers/text-and-data-mining","start":{"date-time":"2026-01-02T00:00:00Z","timestamp":1767312000000,"date-parts":[[2026,1,2]]},"delay-in-days":0,"content-version":"vor"}],"subject":[],"abstract":null,"language":"en","relation":{},"resource":{"primary":{"URL":"https://www.nature.com/articles/s43018-025-01068-0"}},"subtitle":[],"assertion":[{"name":"received","group":{"name":"ArticleHistory","label":"Article History"},"label":"Received","order":1,"value":"9 September 2024"},{"name":"accepted","group":{"name":"ArticleHistory","label":"Article History"},"label":"Accepted","order":2,"value":"6 October 2025"},{"name":"first_online","group":{"name":"ArticleHistory","label":"Article History"},"label":"First Online","order":3,"value":"2 January 2026"},{"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"},"order":1,"value":"T.A.C. is a cofounder of Gritstone Oncology and holds equity. T.A.C. also holds equity in An2H. T.A.C. acknowledges grant funding from Bristol-Myers Squibb, AstraZeneca, Illumina, Pfizer, An2H and Eisai. T.A.C. has served as an advisor for Bristol-Myers, MedImmune, Squibb, Illumina, Eisai, AstraZeneca and An2H. T.A.C. is an inventor on intellectual property held by Memorial Sloan Kettering Cancer Center on using TMB to predict immunotherapy response, with pending patent, which has been licensed to PGDx. T.A.C. is on the advisory board of Cell. N.R. acknowledges research support from Pfizer, REPARE Therapeutics, Invitae and Bristol-Myers Squibb. The other authors declare no competing interests."}],"deposited":{"date-time":"2026-01-02T10:01:49Z","timestamp":1767348109000,"date-parts":[[2026,1,2]]},"issn-type":[{"type":"electronic","value":"2662-1347"}],"published":{"date-parts":[[2026,1,2]]},"publisher":"Springer Science and Business Media LLC","reference":[{"DOI":"10.1056/NEJMoa1602252","key":"1068_CR1","year":"2016","issue":null,"author":"RL Ferris","volume":"375","first-page":"1856","unstructured":"Ferris, R. L. et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 375, 1856–1867 (2016).","article-title":null,"journal-title":"N. Engl. J. Med.","doi-asserted-by":"publisher"},{"DOI":"10.1016/S0140-6736(19)32591-7","key":"1068_CR2","year":"2019","issue":null,"author":"B Burtness","volume":"394","first-page":"1915","unstructured":"Burtness, B. et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet 394, 1915–1928 (2019).","article-title":null,"journal-title":"Lancet","doi-asserted-by":"publisher"},{"DOI":"10.1126/science.aar4060","key":"1068_CR3","year":"2018","issue":null,"author":"A Ribas","volume":"359","first-page":"1350","unstructured":"Ribas, A. & Wolchok, J. D. Cancer immunotherapy using checkpoint blockade. Science 359, 1350–1355 (2018).","article-title":null,"journal-title":"Science","doi-asserted-by":"publisher"},{"DOI":"10.1038/nrd.2018.210","key":"1068_CR4","year":"2018","issue":null,"author":"J Tang","volume":"17","first-page":"854","unstructured":"Tang, J. et al. Trial watch: the clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors. Nat. Rev. Drug Discov. 17, 854–855 (2018).","article-title":null,"journal-title":"Nat. Rev. Drug Discov.","doi-asserted-by":"publisher"},{"DOI":"10.1158/2159-8290.CD-20-1760","key":"1068_CR5","year":"2021","issue":null,"author":"AA Shamseddine","volume":"11","first-page":"1896","unstructured":"Shamseddine, A. A., Burman, B., Lee, N. Y., Zamarin, D. & Riaz, N. Tumor Immunity and immunotherapy for HPV-related cancers. Cancer Discov. 11, 1896–1912 (2021).","article-title":null,"journal-title":"Cancer Discov.","doi-asserted-by":"publisher"},{"DOI":"10.1158/1078-0432.CCR-09-0265","key":"1068_CR6","year":"2009","issue":null,"author":"MZ Dewan","volume":"15","first-page":"5379","unstructured":"Dewan, M. Z. et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin. Cancer Res. 15, 5379–5388 (2009).","article-title":null,"journal-title":"Clin. Cancer Res.","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.it.2018.06.001","key":"1068_CR7","year":"2018","issue":null,"author":"ME Rodriguez-Ruiz","volume":"39","first-page":"644","unstructured":"Rodriguez-Ruiz, M. E., Vanpouille-Box, C., Melero, I., Formenti, S. C. & Demaria, S. Immunological mechanisms responsible for radiation-induced abscopal effect. Trends Immunol. 39, 644–655 (2018).","article-title":null,"journal-title":"Trends Immunol.","doi-asserted-by":"publisher"},{"DOI":"10.1038/s41568-020-0246-1","key":"1068_CR8","year":"2020","issue":null,"author":"M McLaughlin","volume":"20","first-page":"203","unstructured":"McLaughlin, M. et al. Inflammatory microenvironment remodelling by tumour cells after radiotherapy. Nat. Rev. Cancer 20, 203–217 (2020).","article-title":null,"journal-title":"Nat. Rev. Cancer","doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMoa1709937","key":"1068_CR9","year":"2017","issue":null,"author":"SJ Antonia","volume":"377","first-page":"1919","unstructured":"Antonia, S. J. et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N. Engl. J. Med. 377, 1919–1929 (2017).","article-title":null,"journal-title":"N. Engl. J. Med.","doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMoa2032125","key":"1068_CR10","year":"2021","issue":null,"author":"RJ Kelly","volume":"384","first-page":"1191","unstructured":"Kelly, R. J. et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N. Engl. J. Med. 384, 1191–1203 (2021).","article-title":null,"journal-title":"N. Engl. J. Med.","doi-asserted-by":"publisher"},{"DOI":null,"key":"1068_CR11","year":"1979","issue":null,"author":"HB Stone","volume":"63","first-page":"1229","unstructured":"Stone, H. B., Peters, L. J. & Milas, L. Effect of host immune capability on radiocurability and subsequent transplantability of a murine fibrosarcoma. J. Natl Cancer Inst. 63, 1229–1235 (1979).","article-title":null,"journal-title":"J. Natl Cancer Inst.","doi-asserted-by":null},{"DOI":"10.1182/blood-2009-02-206870","key":"1068_CR12","year":"2009","issue":null,"author":"Y Lee","volume":"114","first-page":"589","unstructured":"Lee, Y. et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood 114, 589–595 (2009).","article-title":null,"journal-title":"Blood","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.immuni.2014.10.019","key":"1068_CR13","year":"2014","issue":null,"author":"L Deng","volume":"41","first-page":"843","unstructured":"Deng, L. et al. STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors. Immunity 41, 843–852 (2014).","article-title":null,"journal-title":"Immunity","doi-asserted-by":"publisher"},{"DOI":"10.1038/nrclinonc.2016.211","key":"1068_CR14","year":"2017","issue":null,"author":"RR Weichselbaum","volume":"14","first-page":"365","unstructured":"Weichselbaum, R. R., Liang, H., Deng, L. & Fu, Y. X. Radiotherapy and immunotherapy: a beneficial liaison?. Nat. Rev. Clin. Oncol. 14, 365–379 (2017).","article-title":null,"journal-title":"Nat. Rev. Clin. Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.ijrobp.2012.12.025","key":"1068_CR15","year":"2013","issue":null,"author":"J Zeng","volume":"86","first-page":"343","unstructured":"Zeng, J. et al. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int. J. Radiat. Oncol. Biol. Phys. 86, 343–349 (2013).","article-title":null,"journal-title":"Int. J. Radiat. Oncol. Biol. Phys.","doi-asserted-by":"publisher"},{"DOI":"10.1172/JCI67313","key":"1068_CR16","year":"2014","issue":null,"author":"L Deng","volume":"124","first-page":"687","unstructured":"Deng, L. et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J. Clin. Invest. 124, 687–695 (2014).","article-title":null,"journal-title":"J. Clin. Invest.","doi-asserted-by":"publisher"},{"DOI":"10.1080/2162402X.2017.1356153","key":"1068_CR17","year":"2017","issue":null,"author":"A Oweida","volume":"6","first-page":"e1356153","unstructured":"Oweida, A. et al. Ionizing radiation sensitizes tumors to PD-L1 immune checkpoint blockade in orthotopic murine head and neck squamous cell carcinoma. Oncoimmunology 6, e1356153 (2017).","article-title":null,"journal-title":"Oncoimmunology","doi-asserted-by":"publisher"},{"DOI":"10.1016/S1470-2045(20)30737-3","key":"1068_CR18","year":"2021","issue":null,"author":"NY Lee","volume":"22","first-page":"450","unstructured":"Lee, N. Y. et al. Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Oncol. 22, 450–462 (2021).","article-title":null,"journal-title":"Lancet Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.ijrobp.2022.09.004","key":"1068_CR19","year":"2022","issue":null,"author":"J Mayadev","volume":"114","first-page":"1058","unstructured":"Mayadev, J. et al. Durvalumab in combination with chemoradiotherapy (CRT) in locally advanced cervical cancer (LACC): radiotherapy (RT) delivery and subgroup analyses from CALLA. Int. J. Radiat. Oncol. Biol. Phys. 114, 1058–1059 (2022).","article-title":null,"journal-title":"Int. J. Radiat. Oncol. Biol. Phys.","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.annonc.2022.08.029","key":"1068_CR20","year":"2022","issue":null,"author":"J Machiels","volume":"33","first-page":"S1399","unstructured":"Machiels, J. et al. Primary results of the phase III KEYNOTE-412 study: pembrolizumab (pembro) with chemoradiation therapy (CRT) vs placebo plus CRT for locally advanced (LA) head and neck squamous cell carcinoma (HNSCC). Ann. Oncol. 33, S1399 (2022).","article-title":null,"journal-title":"Ann. Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMoa1613493","key":"1068_CR21","year":"2017","issue":null,"author":"DP Carbone","volume":"376","first-page":"2415","unstructured":"Carbone, D. P. et al. First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. N. Engl. J. Med. 376, 2415–2426 (2017).","article-title":null,"journal-title":"N. Engl. J. Med.","doi-asserted-by":"publisher"},{"DOI":"10.1158/1078-0432.CCR-20-3771","key":"1068_CR22","year":"2021","issue":null,"author":"H Si","volume":"27","first-page":"1631","unstructured":"Si, H. et al. A blood-based assay for assessment of tumor mutational burden in first-line metastatic NSCLC treatment: results from the MYSTIC study. Clin. Cancer Res. 27, 1631–1640 (2021).","article-title":null,"journal-title":"Clin. Cancer Res.","doi-asserted-by":"publisher"},{"DOI":null,"key":"1068_CR23","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Samstein, R. M. et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat. Genet. 51, 202–206 (2019).","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1136/jitc-2021-003026","key":"1068_CR24","year":"2022","issue":null,"author":"RI Haddad","volume":"10","first-page":null,"unstructured":"Haddad, R. I. et al. Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma. J. Immunother. Cancer 10, e003026 (2022).","article-title":null,"journal-title":"J. Immunother. Cancer","doi-asserted-by":"publisher"},{"DOI":"10.1038/nature14129","key":"1068_CR25","year":"2015","issue":null,"author":"Cancer Genome Atlas Network.","volume":"517","first-page":"576","unstructured":"Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 517, 576–582 (2015).","article-title":null,"journal-title":"Nature","doi-asserted-by":"publisher"},{"DOI":"10.1038/nrc.2018.11","key":"1068_CR26","year":"2018","issue":null,"author":"CR Leemans","volume":"18","first-page":"269","unstructured":"Leemans, C. R., Snijders, P. J. F. & Brakenhoff, R. H. The molecular landscape of head and neck cancer. Nat. Rev. Cancer 18, 269–282 (2018).","article-title":null,"journal-title":"Nat. Rev. Cancer","doi-asserted-by":"publisher"},{"DOI":"10.1016/S1470-2045(23)00013-X","key":"1068_CR27","year":"2023","issue":null,"author":"H Mehanna","volume":"24","first-page":"239","unstructured":"Mehanna, H. et al. Prognostic implications of p16 and HPV discordance in oropharyngeal cancer (HNCIG-EPIC-OPC): a multicentre, multinational, individual patient data analysis. Lancet Oncol. 24, 239–251 (2023).","article-title":null,"journal-title":"Lancet Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1186/s13059-016-1092-z","key":"1068_CR28","year":"2016","issue":null,"author":"Y Senbabaoglu","volume":"17","first-page":null,"unstructured":"Senbabaoglu, Y. et al. Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures. Genome Biol. 17, 231 (2016).","article-title":null,"journal-title":"Genome Biol.","doi-asserted-by":"publisher"},{"DOI":"10.1186/s13059-017-1349-1","key":"1068_CR29","year":"2017","issue":null,"author":"D Aran","volume":"18","first-page":null,"unstructured":"Aran, D., Hu, Z. & Butte, A. J. xCell: digitally portraying the tissue cellular heterogeneity landscape. Genome Biol. 18, 220 (2017).","article-title":null,"journal-title":"Genome Biol.","doi-asserted-by":"publisher"},{"DOI":"10.1038/s41591-021-01579-0","key":"1068_CR30","year":"2021","issue":null,"author":"T Powles","volume":"27","first-page":"2200","unstructured":"Powles, T. et al. Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 trial. Nat. Med. 27, 2200–2211 (2021).","article-title":null,"journal-title":"Nat. Med.","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.immuni.2019.08.004","key":"1068_CR31","year":"2019","issue":null,"author":"V Thorsson","volume":"51","first-page":"411","unstructured":"Thorsson, V. et al. The immune landscape of cancer. Immunity 51, 411–412 (2019).","article-title":null,"journal-title":"Immunity","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.labinv.2023.100063","key":"1068_CR32","year":"2023","issue":null,"author":"L Vanhersecke","volume":"103","first-page":null,"unstructured":"Vanhersecke, L. et al. Standardized pathology screening of mature tertiary lymphoid structures in cancers. Lab. Invest. 103, 100063 (2023).","article-title":null,"journal-title":"Lab. Invest.","doi-asserted-by":"publisher"},{"DOI":"10.1038/s41586-019-1914-8","key":"1068_CR33","year":"2020","issue":null,"author":"R Cabrita","volume":"577","first-page":"561","unstructured":"Cabrita, R. et al. Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature 577, 561–565 (2020).","article-title":null,"journal-title":"Nature","doi-asserted-by":"publisher"},{"DOI":"10.1002/path.4953","key":"1068_CR34","year":"2017","issue":null,"author":"K Poropatich","volume":"243","first-page":"354","unstructured":"Poropatich, K. et al. Comprehensive T-cell immunophenotyping and next-generation sequencing of human papillomavirus (HPV)-positive and HPV-negative head and neck squamous cell carcinomas. J. Pathol. 243, 354–365 (2017).","article-title":null,"journal-title":"J. Pathol.","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.immuni.2019.03.009","key":"1068_CR35","year":"2019","issue":null,"author":"R Zilionis","volume":"50","first-page":"1317","unstructured":"Zilionis, R. et al. Single-cell transcriptomics of human and mouse lung cancers reveals conserved myeloid populations across individuals and species. Immunity 50, 1317–1334 (2019).","article-title":null,"journal-title":"Immunity","doi-asserted-by":"publisher"},{"DOI":"10.1038/s41586-022-05435-0","key":"1068_CR36","year":"2022","issue":null,"author":"JL Galeano Nino","volume":"611","first-page":"810","unstructured":"Galeano Nino, J. L. et al. Effect of the intratumoral microbiota on spatial and cellular heterogeneity in cancer. Nature 611, 810–817 (2022).","article-title":null,"journal-title":"Nature","doi-asserted-by":"publisher"},{"DOI":"10.1126/science.aay9189","key":"1068_CR37","year":"2020","issue":null,"author":"D Nejman","volume":"368","first-page":"973","unstructured":"Nejman, D. et al. The human tumor microbiome is composed of tumor type-specific intracellular bacteria. Science 368, 973–980 (2020).","article-title":null,"journal-title":"Science","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.cell.2024.03.021","key":"1068_CR38","year":"2024","issue":null,"author":"TW Battaglia","volume":"187","first-page":"2324","unstructured":"Battaglia, T. W. et al. A pan-cancer analysis of the microbiome in metastatic cancer. Cell 187, 2324–2335 (2024).","article-title":null,"journal-title":"Cell","doi-asserted-by":"publisher"},{"DOI":"10.1038/nbt.1868","key":"1068_CR39","year":"2011","issue":null,"author":"AD Kostic","volume":"29","first-page":"393","unstructured":"Kostic, A. D. et al. PathSeq: software to identify or discover microbes by deep sequencing of human tissue. Nat. Biotechnol. 29, 393–396 (2011).","article-title":null,"journal-title":"Nat. Biotechnol.","doi-asserted-by":"publisher"},{"DOI":"10.1186/s13059-018-1568-0","key":"1068_CR40","year":"2018","issue":null,"author":"FP Breitwieser","volume":"19","first-page":null,"unstructured":"Breitwieser, F. P., Baker, D. N. & Salzberg, S. L. KrakenUniq: confident and fast metagenomics classification using unique k-mer counts. Genome Biol. 19, 198 (2018).","article-title":null,"journal-title":"Genome Biol.","doi-asserted-by":"publisher"},{"DOI":"10.1128/mbio.01607-23","key":"1068_CR41","year":"2023","issue":null,"author":"A Gihawi","volume":"14","first-page":"e0160723","unstructured":"Gihawi, A. et al. Major data analysis errors invalidate cancer microbiome findings. mBio 14, e0160723 (2023).","article-title":null,"journal-title":"mBio","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.phrs.2012.11.006","key":"1068_CR42","year":"2013","issue":null,"author":"WG Wade","volume":"69","first-page":"137","unstructured":"Wade, W. G. The oral microbiome in health and disease. Pharmacol. Res. 69, 137–143 (2013).","article-title":null,"journal-title":"Pharmacol. Res.","doi-asserted-by":"publisher"},{"DOI":"10.4103/jomfp.JOMFP_304_18","key":"1068_CR43","year":"2019","issue":null,"author":"PN Deo","volume":"23","first-page":"122","unstructured":"Deo, P. N. & Deshmukh, R. Oral microbiome: unveiling the fundamentals. J. Oral Maxillofac. Pathol. 23, 122–128 (2019).","article-title":null,"journal-title":"J. Oral Maxillofac. Pathol.","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.chom.2020.12.001","key":"1068_CR44","year":"2021","issue":null,"author":"AB Dohlman","volume":"29","first-page":"281","unstructured":"Dohlman, A. B. et al. The cancer microbiome atlas: a pan-cancer comparative analysis to distinguish tissue-resident microbiota from contaminants. Cell Host Microbe 29, 281–298 (2021).","article-title":null,"journal-title":"Cell Host Microbe","doi-asserted-by":"publisher"},{"DOI":"10.1038/s41587-021-01070-8","key":"1068_CR45","year":"2022","issue":null,"author":"D Chowell","volume":"40","first-page":"499","unstructured":"Chowell, D. et al. Improved prediction of immune checkpoint blockade efficacy across multiple cancer types. Nat. Biotechnol. 40, 499–506 (2022).","article-title":null,"journal-title":"Nat. Biotechnol.","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.cell.2017.10.044","key":"1068_CR46","year":"2017","issue":null,"author":"SV Puram","volume":"171","first-page":"1611","unstructured":"Puram, S. V. et al. Single-cell transcriptomic analysis of primary and metastatic tumor ecosystems in head and neck cancer. Cell 171, 1611–1624 (2017).","article-title":null,"journal-title":"Cell","doi-asserted-by":"publisher"},{"DOI":"10.1186/s12943-023-01769-z","key":"1068_CR47","year":"2023","issue":null,"author":"Y Gong","volume":"22","first-page":null,"unstructured":"Gong, Y. et al. The tumor ecosystem in head and neck squamous cell carcinoma and advances in ecotherapy. Mol. Cancer 22, 68 (2023).","article-title":null,"journal-title":"Mol. Cancer","doi-asserted-by":"publisher"},{"DOI":"10.1038/s41591-023-02371-y","key":"1068_CR48","year":"2023","issue":null,"author":"Y Chu","volume":"29","first-page":"1550","unstructured":"Chu, Y. et al. Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistance. Nat. Med. 29, 1550–1562 (2023).","article-title":null,"journal-title":"Nat. Med.","doi-asserted-by":"publisher"},{"DOI":"10.1038/s41571-022-00689-z","key":"1068_CR49","year":"2022","issue":null,"author":"A Chow","volume":"19","first-page":"775","unstructured":"Chow, A., Perica, K., Klebanoff, C. A. & Wolchok, J. D. Clinical implications of T cell exhaustion for cancer immunotherapy. Nat. Rev. Clin. Oncol. 19, 775–790 (2022).","article-title":null,"journal-title":"Nat. Rev. Clin. Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.ijrobp.2022.09.003","key":"1068_CR50","year":"2022","issue":null,"author":"LK Mell","volume":"114","first-page":"1058","unstructured":"Mell, L. K. et al. Radiotherapy with durvalumab vs. cetuximab in patients with locoregionally advanced head and neck cancer and a contraindication to cisplatin: phase II results of NRG-HN004. Int. J. Radiat. Oncol. Biol. Phys. 114, 1058 (2022).","article-title":null,"journal-title":"Int. J. Radiat. Oncol. Biol. Phys.","doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.2022.40.16_suppl.6007","key":"1068_CR51","year":"2022","issue":null,"author":"DA Clump","volume":"40","first-page":"6007","unstructured":"Clump, D. A. et al. A randomized phase II study evaluating concurrent or sequential fixed-dose immune therapy in combination with cisplatin and intensity-modulated radiotherapy in intermediate- or high-risk, previously untreated, locally advanced head and neck cancer (LA SCCHN). J. Clin. Oncol. 40, 6007 (2022).","article-title":null,"journal-title":"J. Clin. Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1073/pnas.2213835119","key":"1068_CR52","year":"2022","issue":null,"author":"X Zhao","volume":"119","first-page":null,"unstructured":"Zhao, X. et al. Somatic 9p24.1 alterations in HPV− head and neck squamous cancer dictate immune microenvironment and anti-PD-1 checkpoint inhibitor activity. Proc. Natl Acad. Sci. USA 119, e2213835119 (2022).","article-title":null,"journal-title":"Proc. Natl Acad. Sci. USA","doi-asserted-by":"publisher"},{"DOI":"10.1038/s43018-022-00450-6","key":"1068_CR53","year":"2022","issue":null,"author":"LB Darragh","volume":"3","first-page":"1300","unstructured":"Darragh, L. B. et al. A phase I/Ib trial and biological correlate analysis of neoadjuvant SBRT with single-dose durvalumab in HPV-unrelated locally advanced HNSCC. Nat. Cancer 3, 1300–1317 (2022).","article-title":null,"journal-title":"Nat. Cancer","doi-asserted-by":"publisher"},{"DOI":"10.1038/s41467-022-34676-w","key":"1068_CR54","year":"2022","issue":null,"author":"LB Darragh","volume":"13","first-page":null,"unstructured":"Darragh, L. B. et al. Elective nodal irradiation mitigates local and systemic immunity generated by combination radiation and immunotherapy in head and neck tumors. Nat. Commun. 13, 7015 (2022).","article-title":null,"journal-title":"Nat. Commun.","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.ccell.2023.04.019","key":"1068_CR55","year":"2023","issue":null,"author":"L Wang","volume":"41","first-page":"1294","unstructured":"Wang, L. et al. YTHDF2 inhibition potentiates radiotherapy antitumor efficacy. Cancer Cell 41, 1294–1308 (2023).","article-title":null,"journal-title":"Cancer Cell","doi-asserted-by":"publisher"},{"DOI":"10.1038/s43018-022-00456-0","key":"1068_CR56","year":"2022","issue":null,"author":"Y Nishiga","volume":"3","first-page":"1351","unstructured":"Nishiga, Y. et al. Radiotherapy in combination with CD47 blockade elicits a macrophage-mediated abscopal effect. Nat. Cancer 3, 1351–1366 (2022).","article-title":null,"journal-title":"Nat. Cancer","doi-asserted-by":"publisher"},{"DOI":"10.1126/science.abc4552","key":"1068_CR57","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Sepich-Poore, G. D. et al. The microbiome and human cancer. Science 371, eabc4552 (2021).","article-title":null,"journal-title":null,"doi-asserted-by":"crossref"},{"DOI":"10.1038/nature11234","key":"1068_CR58","year":"2012","issue":null,"author":"Human Microbiome Project Consortium.","volume":"486","first-page":"207","unstructured":"Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. Nature 486, 207–214 (2012).","article-title":null,"journal-title":"Nature","doi-asserted-by":"publisher"},{"DOI":"10.1038/s41579-018-0089-x","key":"1068_CR59","year":"2018","issue":null,"author":"RJ Lamont","volume":"16","first-page":"745","unstructured":"Lamont, R. J., Koo, H. & Hajishengallis, G. The oral microbiota: dynamic communities and host interactions. Nat. Rev. Microbiol. 16, 745–759 (2018).","article-title":null,"journal-title":"Nat. Rev. Microbiol.","doi-asserted-by":"publisher"},{"DOI":"10.1016/S1368-8375(98)80012-2","key":"1068_CR60","year":"1998","issue":null,"author":"KN Nagy","volume":"34","first-page":"304","unstructured":"Nagy, K. N., Sonkodi, I., Szoke, I., Nagy, E. & Newman, H. N. The microflora associated with human oral carcinomas. Oral Oncol. 34, 304–308 (1998).","article-title":null,"journal-title":"Oral Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1371/journal.ppat.1003933","key":"1068_CR61","year":"2014","issue":null,"author":"SE Whitmore","volume":"10","first-page":"e1003933","unstructured":"Whitmore, S. E. & Lamont, R. J. Oral bacteria and cancer. PLoS Pathog. 10, e1003933 (2014).","article-title":null,"journal-title":"PLoS Pathog.","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.oraloncology.2019.104453","key":"1068_CR62","year":"2019","issue":null,"author":"E Orlandi","volume":"99","first-page":null,"unstructured":"Orlandi, E. et al. Potential role of microbiome in oncogenesis, outcome prediction and therapeutic targeting for head and neck cancer. Oral Oncol. 99, 104453 (2019).","article-title":null,"journal-title":"Oral Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1093/annonc/mdw224","key":"1068_CR63","year":"2016","issue":null,"author":"D Hashim","volume":"27","first-page":"1619","unstructured":"Hashim, D. et al. The role of oral hygiene in head and neck cancer: results from International Head and Neck Cancer Epidemiology (INHANCE) consortium. Ann. Oncol. 27, 1619–1625 (2016).","article-title":null,"journal-title":"Ann. Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.cell.2019.07.008","key":"1068_CR64","year":"2019","issue":null,"author":"E Riquelme","volume":"178","first-page":"795","unstructured":"Riquelme, E. et al. Tumor microbiome diversity and composition influence pancreatic cancer outcomes. Cell 178, 795–806 (2019).","article-title":null,"journal-title":"Cell","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.chom.2013.07.007","key":"1068_CR65","year":"2013","issue":null,"author":"AD Kostic","volume":"14","first-page":"207","unstructured":"Kostic, A. D. et al. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe 14, 207–215 (2013).","article-title":null,"journal-title":"Cell Host Microbe","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.it.2018.09.007","key":"1068_CR66","year":"2018","issue":null,"author":"AP Cogdill","volume":"39","first-page":"900","unstructured":"Cogdill, A. P., Gaudreau, P. O., Arora, R., Gopalakrishnan, V. & Wargo, J. A. The impact of intratumoral and gastrointestinal microbiota on systemic cancer therapy. Trends Immunol. 39, 900–920 (2018).","article-title":null,"journal-title":"Trends Immunol.","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.cell.2023.03.011","key":"1068_CR67","year":"2023","issue":null,"author":"MJ Bender","volume":"186","first-page":"1846","unstructured":"Bender, M. J. et al. Dietary tryptophan metabolite released by intratumoral Lactobacillus reuteri facilitates immune checkpoint inhibitor treatment. Cell 186, 1846–1862 (2023).","article-title":null,"journal-title":"Cell","doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.23.01488","key":"1068_CR68","year":"2024","issue":null,"author":"A Elkrief","volume":"42","first-page":"3339","unstructured":"Elkrief, A. et al. Intratumoral Escherichia is associated with improved survival to single-agent immune checkpoint inhibition in patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 42, 3339–3349 (2024).","article-title":null,"journal-title":"J. Clin. Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1158/2159-8290.CD-22-0201","key":"1068_CR69","year":"2022","issue":null,"author":"AG Goubet","volume":"12","first-page":"2280","unstructured":"Goubet, A. G. et al. Escherichia coli-specific CXCL13-producing TFH are associated with clinical efficacy of neoadjuvant PD-1 blockade against muscle-invasive bladder cancer. Cancer Discov. 12, 2280–2307 (2022).","article-title":null,"journal-title":"Cancer Discov.","doi-asserted-by":"publisher"},{"DOI":"10.1038/s43018-025-01067-1","key":"1068_CR70","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Silver, N. et al. Intratumoral bacteria are immunosuppressive and promote immunotherapy resistance. Nat. Cancer https://doi.org/10.1038/s43018-025-01067-1 (in the press).","article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1093/bioinformatics/btz363","key":"1068_CR71","year":"2019","issue":null,"author":"G Sturm","volume":"35","first-page":"i436","unstructured":"Sturm, G. et al. Comprehensive evaluation of transcriptome-based cell-type quantification methods for immuno-oncology. Bioinformatics 35, i436–i445 (2019).","article-title":null,"journal-title":"Bioinformatics","doi-asserted-by":"publisher"},{"DOI":"10.1093/nar/gkae267","key":"1068_CR72","year":"2024","issue":null,"author":"H Nguyen","volume":"52","first-page":"4761","unstructured":"Nguyen, H., Nguyen, H., Tran, D., Draghici, S. & Nguyen, T. Fourteen years of cellular deconvolution: methodology, applications, technical evaluation and outstanding challenges. Nucleic Acids Res. 52, 4761–4783 (2024).","article-title":null,"journal-title":"Nucleic Acids Res.","doi-asserted-by":"publisher"},{"DOI":"10.1093/bioinformatics/btp324","key":"1068_CR73","year":"2009","issue":null,"author":"H Li","volume":"25","first-page":"1754","unstructured":"Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows–Wheeler transform. Bioinformatics 25, 1754–1760 (2009).","article-title":null,"journal-title":"Bioinformatics","doi-asserted-by":"publisher"},{"DOI":"10.1101/gr.107524.110","key":"1068_CR74","year":"2010","issue":null,"author":"A McKenna","volume":"20","first-page":"1297","unstructured":"McKenna, A. et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 20, 1297–1303 (2010).","article-title":null,"journal-title":"Genome Res.","doi-asserted-by":"publisher"},{"DOI":"10.1038/ng.806","key":"1068_CR75","year":"2011","issue":null,"author":"MA DePristo","volume":"43","first-page":"491","unstructured":"DePristo, M. A. et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat. Genet. 43, 491–498 (2011).","article-title":null,"journal-title":"Nat. Genet.","doi-asserted-by":"publisher"},{"DOI":"10.1101/gr.129684.111","key":"1068_CR76","year":"2012","issue":null,"author":"DC Koboldt","volume":"22","first-page":"568","unstructured":"Koboldt, D. C. et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. 22, 568–576 (2012).","article-title":null,"journal-title":"Genome Res.","doi-asserted-by":"publisher"},{"DOI":"10.1093/bioinformatics/bts271","key":"1068_CR77","year":"2012","issue":null,"author":"CT Saunders","volume":"28","first-page":"1811","unstructured":"Saunders, C. T. et al. Strelka: accurate somatic small-variant calling from sequenced tumor–normal sample pairs. Bioinformatics 28, 1811–1817 (2012).","article-title":null,"journal-title":"Bioinformatics","doi-asserted-by":"publisher"},{"DOI":"10.1093/bioinformatics/btr665","key":"1068_CR78","year":"2012","issue":null,"author":"DE Larson","volume":"28","first-page":"311","unstructured":"Larson, D. E. et al. SomaticSniper: identification of somatic point mutations in whole genome sequencing data. Bioinformatics 28, 311–317 (2012).","article-title":null,"journal-title":"Bioinformatics","doi-asserted-by":"publisher"},{"DOI":"10.1038/ng.3036","key":"1068_CR79","year":"2014","issue":null,"author":"A Rimmer","volume":"46","first-page":"912","unstructured":"Rimmer, A. et al. Integrating mapping-, assembly- and haplotype-based approaches for calling variants in clinical sequencing applications. Nat. Genet. 46, 912–918 (2014).","article-title":null,"journal-title":"Nat. Genet.","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.cels.2018.03.002","key":"1068_CR80","year":"2018","issue":null,"author":"K Ellrott","volume":"6","first-page":"271","unstructured":"Ellrott, K. et al. Scalable open science approach for mutation calling of tumor exomes using multiple genomic pipelines. Cell Syst. 6, 271–281 (2018).","article-title":null,"journal-title":"Cell Syst.","doi-asserted-by":"publisher"},{"DOI":"10.1038/s41598-019-45839-z","key":"1068_CR81","year":"2019","issue":null,"author":"HM Amemiya","volume":"9","first-page":null,"unstructured":"Amemiya, H. M., Kundaje, A. & Boyle, A. P. The ENCODE blacklist: identification of problematic regions of the genome. Sci. Rep. 9, 9354 (2019).","article-title":null,"journal-title":"Sci. Rep.","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.cell.2017.09.028","key":"1068_CR82","year":"2017","issue":null,"author":"N Riaz","volume":"171","first-page":"934","unstructured":"Riaz, N. et al. Tumor and microenvironment evolution during immunotherapy with nivolumab. Cell 171, 934–949 (2017).","article-title":null,"journal-title":"Cell","doi-asserted-by":"publisher"},{"DOI":"10.1186/s13059-016-0893-4","key":"1068_CR83","year":"2016","issue":null,"author":"R Rosenthal","volume":"17","first-page":null,"unstructured":"Rosenthal, R., McGranahan, N., Herrero, J., Taylor, B. S. & Swanton, C. DeconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution. Genome Biol. 17, 31 (2016).","article-title":null,"journal-title":"Genome Biol.","doi-asserted-by":"publisher"},{"DOI":"10.1038/s41586-020-1943-3","key":"1068_CR84","year":"2020","issue":null,"author":"LB Alexandrov","volume":"578","first-page":"94","unstructured":"Alexandrov, L. B. et al. The repertoire of mutational signatures in human cancer. Nature 578, 94–101 (2020).","article-title":null,"journal-title":"Nature","doi-asserted-by":"publisher"},{"DOI":"10.1007/978-1-0716-0389-5_3","key":"1068_CR85","year":"2020","issue":null,"author":"S Kawaguchi","volume":"2131","first-page":"31","unstructured":"Kawaguchi, S. & Matsuda, F. High-definition genomic analysis of HLA genes via comprehensive HLA allele genotyping. Methods Mol. Biol. 2131, 31–38 (2020).","article-title":null,"journal-title":"Methods Mol. Biol.","doi-asserted-by":"publisher"},{"DOI":"10.3389/fimmu.2021.652258","key":"1068_CR86","year":"2021","issue":null,"author":"P Liu","volume":"12","first-page":null,"unstructured":"Liu, P. et al. Benchmarking the human leukocyte antigen typing performance of three assays and seven next-generation sequencing-based algorithms. Front. Immunol. 12, 652258 (2021).","article-title":null,"journal-title":"Front. Immunol.","doi-asserted-by":"publisher"},{"DOI":"10.1093/nar/gkw520","key":"1068_CR87","year":"2016","issue":null,"author":"R Shen","volume":"44","first-page":"e131","unstructured":"Shen, R. & Seshan, V. E. FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing. Nucleic Acids Res. 44, e131 (2016).","article-title":null,"journal-title":"Nucleic Acids Res.","doi-asserted-by":"publisher"},{"DOI":"10.1101/508127","key":"1068_CR88","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Leshchiner, I. et al. Comprehensive analysis of tumour initiation, spatial and temporal progression under multiple lines of treatment. Preprint at bioRxiv https://doi.org/10.1101/508127 (2019).","article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1093/bioinformatics/bts635","key":"1068_CR89","year":"2013","issue":null,"author":"A Dobin","volume":"29","first-page":"15","unstructured":"Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15–21 (2013).","article-title":null,"journal-title":"Bioinformatics","doi-asserted-by":"publisher"},{"DOI":"10.1093/bioinformatics/btt656","key":"1068_CR90","year":"2014","issue":null,"author":"Y Liao","volume":"30","first-page":"923","unstructured":"Liao, Y., Smyth, G. K. & Shi, W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 30, 923–930 (2014).","article-title":null,"journal-title":"Bioinformatics","doi-asserted-by":"publisher"},{"DOI":"10.1186/s13059-014-0550-8","key":"1068_CR91","year":"2014","issue":null,"author":"MI Love","volume":"15","first-page":null,"unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).","article-title":null,"journal-title":"Genome Biol.","doi-asserted-by":"publisher"},{"DOI":"10.1101/2021.08.19.456930","key":"1068_CR92","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Katz, A. et al. CytoPro: a computational platform for accurate and robust assessment of cell contributions in bulk expression from diverse tissues and conditions. Preprint at bioRxiv https://doi.org/10.1101/2021.08.19.456930 (2021).","article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1093/bioinformatics/btu033","key":"1068_CR93","year":"2014","issue":null,"author":"A Stamatakis","volume":"30","first-page":"1312","unstructured":"Stamatakis, A. RAxML version 8: a tool for phylogenetic analysis and post-analysis of large phylogenies. Bioinformatics 30, 1312–1313 (2014).","article-title":null,"journal-title":"Bioinformatics","doi-asserted-by":"publisher"},{"DOI":"10.1093/bioinformatics/bty501","key":"1068_CR94","year":"2018","issue":null,"author":"MA Walker","volume":"34","first-page":"4287","unstructured":"Walker, M. A. et al. GATK PathSeq: a customizable computational tool for the discovery and identification of microbial sequences in libraries from eukaryotic hosts. Bioinformatics 34, 4287–4289 (2018).","article-title":null,"journal-title":"Bioinformatics","doi-asserted-by":"publisher"},{"DOI":"10.17044/scilifelab.21299541.v1","key":"1068_CR95","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Oskolkov, N. KrakenUniq database based on complete microbial genomes from NCBI RefSeq, May 2020. FigShare https://doi.org/10.17044/scilifelab.21299541.v1 (2022).","article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1038/nmeth.3869","key":"1068_CR96","year":"2016","issue":null,"author":"BJ Callahan","volume":"13","first-page":"581","unstructured":"Callahan, B. J. et al. DADA2: high-resolution sample inference from Illumina amplicon data. Nat. Methods 13, 581–583 (2016).","article-title":null,"journal-title":"Nat. Methods","doi-asserted-by":"publisher"},{"DOI":"10.1371/journal.pone.0061217","key":"1068_CR97","year":"2013","issue":null,"author":"PJ McMurdie","volume":"8","first-page":null,"unstructured":"McMurdie, P. J. & Holmes, S. phyloseq: an R package for reproducible interactive analysis and graphics of microbiome census data. PLoS ONE 8, e61217 (2013).","article-title":null,"journal-title":"PLoS ONE","doi-asserted-by":"publisher"}],"short-title":[],"update-policy":"https://doi.org/10.1007/springer_crossmark_policy","alternative-id":["1068"],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"original-title":[],"container-title":["Nature Cancer"],"reference-count":97,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2026,1,2]]},"references-count":97,"short-container-title":["Nat Cancer"],"is-referenced-by-count":1},"unpaywall":{"doi":"10.1038/s43018-025-01068-0","is_oa":false,"title":"Tumor ecosystem and microbiome features associated with efficacy and resistance to avelumab plus chemoradiotherapy in head and neck cancer","updated":"2026-01-03T00:50:51+00:00","published_date":"2026-01-02","best_oa_location":null}},"created_at":"2026-01-11T11:19:33.869Z","updated_at":"2026-01-21T12:05:26.220Z","tags":[{"paper_doi":"10.1038/s43018-025-01068-0","tag_type":"category","value":"Oncology","value_numeric":null},{"paper_doi":"10.1038/s43018-025-01068-0","tag_type":"condition","value":"Head and Neck Cancer","value_numeric":null},{"paper_doi":"10.1038/s43018-025-01068-0","tag_type":"generic","value":"avelumab","value_numeric":null},{"paper_doi":"10.1038/s43018-025-01068-0","tag_type":"level_of_evidence","value":"2","value_numeric":null},{"paper_doi":"10.1038/s43018-025-01068-0","tag_type":"modality","value":"Chemoradiotherapy","value_numeric":null},{"paper_doi":"10.1038/s43018-025-01068-0","tag_type":"modality","value":"PD-L1 Inhibitor","value_numeric":null},{"paper_doi":"10.1038/s43018-025-01068-0","tag_type":"study_design","value":"Randomized Controlled Trial","value_numeric":null},{"paper_doi":"10.1038/s43018-025-01068-0","tag_type":"warning","value":"Abstract does not report sample size, endpoints, or effect sizes.","value_numeric":null},{"paper_doi":"10.1038/s43018-025-01068-0","tag_type":"warning","value":"Biomarker findings come from translational analyses within an RCT; the design label reflects the parent trial.","value_numeric":null},{"paper_doi":"10.1038/s43018-025-01068-0","tag_type":"warning","value":"Comparative statements in the abstract are qualitative without numeric estimates.","value_numeric":null}],"summaries":{"what_studied":"A translational analysis within a phase 3 international randomized trial (NCT02952586) compared avelumab plus standard-of-care chemoradiotherapy versus placebo/chemoradiotherapy in locally advanced head and neck cancer to identify tumor, microenvironment, and microbiome features linked to outcomes.","key_result":"Patients on avelumab whose tumors had distinct immunologic and genetic features had superior outcomes versus placebo, while those with increased myeloid/neutrophil activity did worse on avelumab than on placebo; these resistant tumors showed intratumoral bacteria, elevated tumor-associated neutrophils, higher systemic neutrophil-to-lymphocyte ratios, and suppressed adaptive immunity.","practice_takeaway":"Benefit from adding avelumab to chemoradiotherapy depended on the tumor ecosystem; neutrophil-dominant, bacteria-bearing tumors aligned with worse outcomes, while distinct immune–genetic profiles aligned with benefit."}}],"initialOffset":7,"fetchConfig":{"kind":"tags","tags":[{"tag_type":"condition","value":"Head and Neck Cancer"}]},"breadcrumbItems":[{"name":"Home","href":"/"},{"name":"Research Hub","href":"/hub"},{"name":"Conditions","href":"/hub/tag/condition"},{"name":"Head and Neck Cancer"}],"hrefConfig":{"basePath":"/hub/papers","webViewQueryParams":{"hub_ctx":"tag","hub_tag_type":"condition","hub_tag_value":"Head and Neck Cancer"}}}]]

Papers